SAN DIEGO, Nov. 9, 2009 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that Phase 1 clinical data will be presented on TRC102 at the 21st Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts. TRC102 is a small molecule inhibitor of base excision repair that reverses resistance to commonly used antimetabolite and alkylating agent chemotherapies. The program targets a unique pathway with the potential for broad application to a wide variety of cancer types. TRC102 is currently being studied as an oral agent in combination with pemetrexed (Alimta(R)) and as an intravenous agent in combination with temozolomide (Temodar(R)). In this Phase 1 trial, oral TRC102 was dose-escalated in combination with standard dose pemetrexed for patients with advanced cancer. The presentation details are as follows:
Abstract Title: A Phase 1 Study of Oral TRC102 (Methoxyamine Hydrochloride), an Inhibitor of Base-excision Repair, to Potentiate the Therapeutic Effects of Pemetrexed in Patients with Advanced Refractory Cancer Presenter: Michael Gordon, MD, Premiere Oncology of Arizona Date and Time: Tuesday Nov 17, 2009, 12:30 PM - 2:30 PM Session Title: Drug Resistance and Modifiers 2 Session ID: Poster Session B Abstract Number: B62 Location: Halls C-D, 2nd Floor, Hynes Convention Center, Boston, MA
About TRACON
TRACON Pharmaceuticals is a privately held biotechnology company focused on the development of products for oncology and ophthalmology treatment, including agents that inhibit angiogenesis. TRACON addresses unmet needs in these areas with first-in-class product candidates that will complement existing therapies. TRC093 is a monoclonal antibody that binds to cleaved collagen to inhibit angiogenesis and tumor growth that began dosing in a Phase 1 clinical trial in cancer patients in July, 2007. TRC105 is a monoclonal antibody that binds CD105 (endoglin) to inhibit angiogenesis that began dosing in a Phase 1 clinical trial in cancer patients in January, 2008. TRC102, a small molecule that reverses resistance to chemotherapeutics, began dosing in 2008 in a Phase 1 trial in combination with Temodar(R) and a Phase 1 trial in combination with Alimta(R). Further information about TRACON Pharmaceuticals can be found at www.traconpharma.com.